Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination: An experimental study in rats

This publication has 26 references indexed in Scilit:

• The Angiotensin II Type 1—Receptor Blocker Candesartan Increases Cerebral Blood Flow, Reduces Infarct Size, and Improves Neurologic Outcome after Transient Cerebral Ischemia in Rats
  Journal of Cerebral Blood Flow & Metabolism, 2004
• l-NAME reduces infarction, neurological deficit and blood–brain barrier disruption following cerebral ischemia in mice
  European Journal of Pharmacology, 2002
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  Published by Elsevier ,2002
• Blockade of Central Angiotensin AT ₁ Receptors Improves Neurological Outcome and Reduces Expression of AP-1 Transcription Factors After Focal Brain Ischemia in Rats
  Stroke, 1999
• To what extent have functional studies of ischaemia in animals been useful in the assessment of potential neuroprotective agents?
  Trends in Pharmacological Sciences, 1998
• L-NAME Reduces Infarct Volume in a Filament Model of Transient Middle Cerebral Artery Occlusion in the Rat Pup
  Pediatric Research, 1995
• Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
  JAMA, 1995
• Failure to prevent selective CA1 neuronal death and reduce cortical infarction following cerebral ischemia with inhibition of nitric oxide synthase
  Neuroscience, 1994
• Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats.
  Stroke, 1986
• Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination.
  Stroke, 1986